B

Bellerophon Therapeutics Inc
F:6L7A

Watchlist Manager
Bellerophon Therapeutics Inc
F:6L7A
Watchlist
Price: 0.35 EUR Market Closed
Market Cap: €3.7m

Net Margin

-194.1%
Current
Improving
by 16.6%
vs 3-y average of -210.7%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-194.1%
=
Net Income
$-9.3m
/
Revenue
$5.6m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-194.1%
=
Net Income
€-9.3m
/
Revenue
$5.6m

Peer Comparison

Country Company Market Cap Net
Margin
US
Bellerophon Therapeutics Inc
F:6L7A
3.7m EUR
Loading...
US
Intuitive Surgical Inc
NASDAQ:ISRG
187.1B USD
Loading...
US
Abbott Laboratories
NYSE:ABT
184.5B USD
Loading...
US
Boston Scientific Corp
NYSE:BSX
139.3B USD
Loading...
US
Stryker Corp
NYSE:SYK
136.2B USD
Loading...
IE
Medtronic PLC
NYSE:MDT
129.3B USD
Loading...
US
Becton Dickinson and Co
NYSE:BDX
57.8B USD
Loading...
DE
Siemens Healthineers AG
XETRA:SHL
47.6B EUR
Loading...
US
IDEXX Laboratories Inc
NASDAQ:IDXX
55.2B USD
Loading...
US
Edwards Lifesciences Corp
NYSE:EW
47.9B USD
Loading...
US
Resmed Inc
NYSE:RMD
37.5B USD
Loading...

Market Distribution

Lower than 88% of companies in the United States of America
Percentile
12th
Based on 15 072 companies
12th percentile
-194.1%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Bellerophon Therapeutics Inc
Glance View

Market Cap
3.7m EUR
Industry
Health Care

Bellerophon Therapeutics, Inc. focuses on developing products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company is headquartered in Warren, New Jersey and currently employs 20 full-time employees. The company went IPO on 2015-02-13. The firm is focused on developing products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The focus of the Company’s clinical program is the continued development of its nitric oxide therapy for patients with pulmonary hypertension (PH) using its delivery system, INOpulse. The firm has three subsidiaries: Bellerophon BCM LLC, Bellerophon Pulse Technologies LLC and Bellerophon Services, Inc. The Company’s INOpulse program is an extension of the technology used in hospitals to deliver continuous flow inhaled nitric oxide. INOpulse program is built on scientific and technical developed for the therapeutic delivery of inhaled nitric oxide. The company is developing INOpulse for the treatment of patients with fibrotic interstitial lung disease (fILD) at a risk for pulmonary hypertension, which includes PH associated with idiopathic pulmonary fibrosis.

6L7A Intrinsic Value
Not Available
B
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-194.1%
=
Net Income
$-9.3m
/
Revenue
$5.6m
What is Bellerophon Therapeutics Inc's current Net Margin?

The current Net Margin for Bellerophon Therapeutics Inc is -194.1%, which is above its 3-year median of -210.7%.

How has Net Margin changed over time?

Over the last 6 months, Bellerophon Therapeutics Inc’s Net Margin has increased from -218.5% to -194.1%. During this period, it reached a low of -240% on Jun 30, 2023 and a high of -173.5% on Oct 30, 2023.

Back to Top